Plain-English translation of NCT07173426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a device called Bioimpedance Analysis (BIA)—a portable scanner that measures fluid in your body—can help doctors manage your heart failure better than standard care alone. If you're admitted to the hospital with worsening heart failure, you may receive regular BIA scans to help guide how much diuretic medication (water pills) you receive. The goal is to help doctors find your body's ideal fluid balance more accurately, which could reduce the need for future hospitalizations.
Many heart failure patients leave the hospital without having enough fluid removed from their bodies, leading to readmission and worsening health. Current methods doctors use to assess fluid buildup—like physical exams and imaging—often aren't accurate enough, especially for people with obesity or kidney disease. This trial is testing whether the new scanner could give doctors a more precise way to guide treatment and prevent complications.
You likely qualify if…
You likely don't qualify if…
If you're in the treatment group, doctors will use a portable BIA scanner on you within 24 hours of admission and then regularly during your hospital stay to measure your body's fluid levels and guide your diuretic therapy. If you're in the standard care group, research staff will do BIA scans at admission and discharge, but doctors won't see those results—they'll treat you as they normally would. Either way, you'll be followed for 90 days after discharge to track whether you need additional diuretics or rehospitalization.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United Kingdom